PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
Philippe Armand(Harvard University), Alex F. Herrera(City of Hope), Jerome Ritz(Dana-Farber Cancer Institute), Jad Bsat(Dana-Farber Cancer Institute), Robert Redd(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Margaret A. Shipp(Broad Institute), Jeffrey L. Wong(Memorial Sloan Kettering Cancer Center), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Yi‐Bin Chen(Massachusetts General Hospital), Sanjay S. Patel(Brigham and Women's Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Scott J. Rodig(Brigham and Women's Hospital), Reid W. Merryman(Harvard University), Mikel Lipschitz(Brigham and Women's Hospital), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Kimberly C. Coleman(Dana-Farber Cancer Institute)
Cited by 13
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k